Palisade Bio (NASDAQ:PALI) Now Covered by Stifel Nicolaus

Stifel Nicolaus began coverage on shares of Palisade Bio (NASDAQ:PALI) in a research note released on Wednesday morning, Marketbeat reports. The brokerage issued a buy rating and a $5.00 target price on the stock.

A number of other equities research analysts have also weighed in on the stock. Weiss Ratings restated a “sell (e+)” rating on shares of Palisade Bio in a report on Thursday, January 22nd. Clear Str upgraded shares of Palisade Bio to a “strong-buy” rating in a research report on Monday, December 29th. B. Riley Financial initiated coverage on Palisade Bio in a report on Friday, January 9th. They issued a “buy” rating and a $7.00 price objective on the stock. Citigroup reissued a “buy” rating on shares of Palisade Bio in a research note on Tuesday, November 11th. Finally, Wall Street Zen lowered Palisade Bio from a “hold” rating to a “sell” rating in a research report on Saturday, February 7th. One analyst has rated the stock with a Strong Buy rating, five have issued a Buy rating and one has issued a Sell rating to the stock. According to data from MarketBeat, the company has an average rating of “Moderate Buy” and an average price target of $13.25.

Palisade Bio Trading Up 6.1%

Shares of Palisade Bio stock opened at $1.90 on Wednesday. The firm has a market capitalization of $283.10 million, a PE ratio of -0.90 and a beta of 1.58. Palisade Bio has a 12 month low of $0.53 and a 12 month high of $2.64. The business’s 50-day moving average price is $1.86 and its 200-day moving average price is $1.57.

Institutional Inflows and Outflows

A number of hedge funds have recently bought and sold shares of PALI. Cetera Investment Advisers purchased a new stake in Palisade Bio in the 4th quarter worth approximately $25,000. Schonfeld Strategic Advisors LLC bought a new position in shares of Palisade Bio during the fourth quarter valued at approximately $26,000. Virtu Financial LLC purchased a new stake in Palisade Bio in the fourth quarter worth $28,000. Atom Investors LP bought a new stake in Palisade Bio in the fourth quarter valued at $33,000. Finally, Barclays PLC purchased a new position in Palisade Bio during the 4th quarter valued at $35,000. Hedge funds and other institutional investors own 11.79% of the company’s stock.

Palisade Bio Company Profile

Palisade Bio, Inc is a clinical‐stage biotechnology company focused on pioneering localized immunotherapies for the treatment of cancer and inflammatory diseases. The company leverages a proprietary prodrug platform designed to activate therapeutic agents selectively within the tumor microenvironment or sites of inflammation. Its core strategy centers on stimulating the innate immune system via toll‐like receptor 9 (TLR9) agonism to drive targeted immune responses while minimizing systemic exposure and toxicity.

The company’s lead product candidate, PDS0108, is an intratumoral TLR9 agonist prodrug currently in Phase 1/2 clinical trials for patients with advanced solid tumors.